1225 related articles for article (PubMed ID: 25523533)
1. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
[TBL] [Abstract][Full Text] [Related]
2. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
[TBL] [Abstract][Full Text] [Related]
3. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
Leoncini M; Toso A; Maioli M; Tropeano F; Badia T; Villani S; Bellandi F
Am Heart J; 2014 Nov; 168(5):792-7. PubMed ID: 25440809
[TBL] [Abstract][Full Text] [Related]
4. Impact of Rosuvastatin in Contrast-Induced Acute Kidney Injury in the Elderly: Post Hoc Analysis of the PRATO-ACS Trial.
Tropeano F; Leoncini M; Toso A; Maioli M; Dabizzi L; Biagini D; Villani S; Bellandi F
J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):159-66. PubMed ID: 26307206
[TBL] [Abstract][Full Text] [Related]
5. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
[TBL] [Abstract][Full Text] [Related]
6. Procalcitonin as an Early Predictor of Contrast-Induced Acute Kidney Injury in Patients With Acute Coronary Syndromes Who Underwent Percutaneous Coronary Intervention.
Kurtul A; Murat SN; Yarlioglues M; Duran M; Ocek AH; Celik IE; Kilic A; Koseoglu C; Oksuz F; Baris VO
Angiology; 2015 Nov; 66(10):957-63. PubMed ID: 25688117
[TBL] [Abstract][Full Text] [Related]
7. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y; Zhu G; Han L; Hou F; Huang W; Liu H; Gan J; Jiang T; Li X; Wang W; Ding S; Jia S; Shen W; Wang D; Sun L; Qiu J; Wang X; Li Y; Deng J; Li J; Xu K; Xu B; Mehran R; Huo Y
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):62-70. PubMed ID: 24076297
[TBL] [Abstract][Full Text] [Related]
8. Impact of Serum Albumin Levels on Contrast-Induced Acute Kidney Injury in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention.
Murat SN; Kurtul A; Yarlioglues M
Angiology; 2015 Sep; 66(8):732-7. PubMed ID: 25260710
[TBL] [Abstract][Full Text] [Related]
9. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
Abaci O; Arat Ozkan A; Kocas C; Cetinkal G; Sukru Karaca O; Baydar O; Kaya A; Gurmen T
Am J Cardiol; 2015 Apr; 115(7):867-71. PubMed ID: 25670636
[TBL] [Abstract][Full Text] [Related]
10. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
11. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
[TBL] [Abstract][Full Text] [Related]
12. Statins for the prevention of contrast-induced acute kidney injury.
Ball T; McCullough PA
Nephron Clin Pract; 2014; 127(1-4):165-71. PubMed ID: 25343843
[TBL] [Abstract][Full Text] [Related]
13. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
[TBL] [Abstract][Full Text] [Related]
14. ACP Journal Club. Early high-dose rosuvastatin prevented contrast-induced acute kidney injury in non-ST-elevation ACS.
Molnar AO; Garg AX
Ann Intern Med; 2014 May; 160(10):JC9. PubMed ID: 24842443
[No Abstract] [Full Text] [Related]
15. Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.
Kocas C; Yildiz A; Abaci O; Karaca OS; Firdin N; Dalgic Y; Bostan C; Ersanli M
Angiology; 2015 Nov; 66(10):964-8. PubMed ID: 25852211
[TBL] [Abstract][Full Text] [Related]
16. Statins and Incidence of Contrast-Induced Acute Kidney Injury Following Coronary Angiography - Five Year Experience at a Tertiary Care Center.
Sreenivasan J; Khan MS; Li H; Zhuo M; Patel A; Fugar S; Tarbutton M; Siddamsetti S; Yadav N
Cardiovasc Revasc Med; 2019 Aug; 20(8):654-658. PubMed ID: 30318173
[TBL] [Abstract][Full Text] [Related]
17. [Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].
Su JZ; Xue Y; Cai WQ; Huang QY; Chai DJ; Chen GL; Wang FB; Chen XP; Zhang DS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Sep; 39(9):807-11. PubMed ID: 22321227
[TBL] [Abstract][Full Text] [Related]
18. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
Kim MJ; Jeon DS; Gwon HC; Kim SJ; Chang K; Kim HS; Tahk SJ;
Clin Cardiol; 2012 Nov; 35(11):700-6. PubMed ID: 22825844
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Dai Y; Huang J; Zeng L; Huang Z; Duan C; Shao S; Chen H; Xue L; Chen J; Tan N; He P; Liu Y; Yu D
Biomed Pharmacother; 2020 Aug; 128():110336. PubMed ID: 32521452
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
